指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

验证北美专家共识声明用于报告肺癌患者COVID-19的CT表现

Validation of the North America expert consensus statement on reporting CT findings for COVID-19 in individuals with lung cancer.
指南 / 共识 · Braz J Med Biol Res · 2023-01-09
一句话结论在肺癌患者中验证RSNA COVID-19 CT报告系统:典型表现者RT-PCR阳性率75%,非典型/阴性者仅9%(P<0.001),肺部受累>25%者病死率83%、>50%者100%。

本研究在巴西圣保罗州立癌症研究所(ICESP)纳入58例已知肺癌、因疑似COVID-19到急诊行胸部CT的成人患者(65±9岁,43%男性),验证RSNA标准化CT报告系统。20例RT-PCR阳性;CT无新发病灶者占43%。RSNA典型表现者RT-PCR阳性率75%,非典型或阴性者仅9%(P<0.001)。按有无进展性疾病分层后诊断准确性更高。肺部炎症范围与病死率强相关:肺部受累>25%者病死率83%,>50%者100%。结果表明胸部CT对COVID-19的诊断和预后价值在存在肺癌相关肺部异常时依然稳健。

要点

  • RSNA典型CT表现者RT-PCR阳性率75%,非典型或阴性者仅9%(P<0.001)。
  • 按有无进展性疾病分层后,CT诊断准确性更高。
  • 肺部受累>25%者病死率83%,>50%者病死率100%。
  • 肺部受累评分对肺癌人群的预后预测价值与非肺癌人群相似。
  • 43%的患者CT无新发肺部病灶。

适用人群与场景

  • 年龄≥18岁、确诊肺癌、因疑似COVID-19到急诊行胸部CT的患者,来自圣保罗州立癌症研究所(ICESP)。

诊断标准与关键阈值

  • 采用放射学会(RSNA)标准化报告系统对胸部CT表现分类(典型、非典型、阴性等)。

研究设计与关键结果

  • 共纳入58例(65±9岁,43%男性),20例RT-PCR阳性;43%的患者CT无新发肺部病灶。
  • RSNA典型表现者RT-PCR阳性率75%,非典型或阴性者仅9%(P<0.001)。
  • 按有无进展性疾病分层后诊断准确性更高。
  • 肺部炎症范围与病死率强相关:肺部受累>25%者病死率83%,>50%者病死率100%。

证据类型、等级与局限

  • 证据类型:验证性研究(对RSNA专家共识报告系统的验证)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在肺癌患者中,RSNA典型CT表现仍提示COVID-19可能(RT-PCR阳性率75%),非典型或阴性者阳性率仅9%,可辅助急诊分流。
  • 肺部受累>25%提示高病死风险(83%),>50%者病死率100%,应加强监护。

指南或共识出处

  • 放射学会(RSNA)关于报告COVID-19胸部CT表现的专家共识声明。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The aim of our study was to validate the use of the standardized Radiological Society of North America (RSNA) reporting system in individuals with known lung cancer who presented to the emergency department with suspected COVID-19. We included patients aged 18 years or older from the Cancer Institute of the State of São Paulo (ICESP) with a confirmed diagnosis of lung cancer, admitted to the emergency department and undergoing chest computed tomography (CT) for suspicion of COVID-19. Comparison between SARS-CoV2 RT-PCR across RSNA categories was performed in all patients and further stratified by diagnosis of lung cancer progression. Among 58 individuals included in the analysis (65±9 years, 43% men), 20 had positive RT-PCR. Less than a half (43%) had no new lung findings in the CT. Positive RT-PCR was present in 75% of those with typical findings according to RSNA and in only 9% when these findings were classified as atypical or negative (P<0.001). Diagnostic accuracy was even higher when stratified by the presence or absence of progressive disease (PD). Extent of pulmonary inflammatory changes was strongly associated with higher mortality, reaching a lethality of 83% in patients with >25% of lung involvement and 100% when there was >50% of lung involvement. The lung involvement score was also highly predictive of prognosis in this population as was reported for non-lung cancer individuals. Collectively, our results demonstrated that diagnostic and prognostic values of chest CT findings in COVID-19 are robust to the presence of lung abnormalities related to lung cancer.

来源:Braz J Med Biol Res,查看原文。版权归原作者所有。

参考来源

  1. Peixoto D, Neves YCS, Generoso G, et al. Validation of the North America expert consensus statement on reporting CT findings for COVID-19 in individuals with lung cancer. Braz J Med Biol Res. 2023. PMID: 36629525. doi:10.1590/1414-431X2022e12376

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。